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Mycobacterium tuberculosis
 
 and the host response
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Mycobacterium tuberculosis
 
 remains a leading cause of morbidity and mortality 
worldwide. Advances reported at a recent international meeting highlight 
insights and controversies in the genetics of 
 
M. tuberculosis
 
 and the infected 
host, the nature of protective immune responses, adaptation of the bacillus to 
host-imposed stresses, animal models, and new techniques.
 
Some hold that research should focus
on a “security council” of “model organ-
isms” whose sole bacterial representative
should be 
 
Escherichia coli
 
 (1). Not so,
according to 559 attendees who traveled
from around the world to the 5th Bi-
ennial Keystone Meeting on Tubercu-
losis (TB) at Whistler, British Columbia
from April 2–6, 2005, under the chair-
manship of Gilla Kaplan, Stewart Cole,
and Clifton Barry III. 
 
Mycobacterium
tuberculosis
 
 (Mtb) poses extraordinary
intellectual and medical challenges, as
 
 
 
40% of its genes are of unknown
function and it has infected 
 
 
 
30% of the
world’s population. These challenges
attract scientists of diverse disciplines
who surprise each other with examples
of biology and biochemistry that the
so-called model organisms lack. Despite
the difficulties of working with a slow-
growing, highly infectious pathogen to
which genetic tools came late and re-
main incomplete, Mtb has become an
uninvited guest at the model organisms’
table. Below, some highlights of the
meeting are related, with emphasis on
work not yet published or only re-
cently reported.
(PDIM) and phenolic glycolipid (PGL),
and the soluble 
 
p
 
-hydroxybenzoic acid
derivative (
 
p
 
-HBAD), and identified
the relevant glycosyltransferases and
methyltransferases that help build these
lipids. All Mtb strains make PDIM and
p-HBAD, whereas PGL is only associ-
ated with some clinical isolates and
enhances their virulence by modulating
the host immune response (Gilla Kaplan,
Newark, NJ) (3). Similarly, Rajesh
Gokhale (New Delhi, India) has de-
coded the synthesis of PDIM, with final
verification furnished by an elegant
retro-biosynthetic approach (4). Studies
combining biochemistry with purified
bacterial components, structural pre-
dictions, and site-directed mutagene-
sis  have defined protein domains in-
volved in each of the catalytic steps of
PDIM synthesis. Both the Gokhale and
Guilhot groups now have Mtb strains
in hand that synthesize modified lipids,
which should enable characterization
of their biological roles.
 
Host genetics and genomics
 
Adrian Hill (Oxford, UK) reviewed
evidence that susceptibility to TB in
humans is a polygenic trait, including
increased concordance of disease in
monozygotic compared with dizygotic
twins, increased susceptibility among
inbred populations, and identification
of numerous genes each of which con-
tributes to susceptibility to a minor ex-
tent that varies in different populations.
Genes encoding HLA-DRB1, vitamin
D receptor, NRAMP-1, and interferon
 
  
 
(IFN-
 
 
 
) have each been implicated
in independent studies. Cathepsin Z
(expressed in early phagosomes), SP110
(human homologue of 
 
Ipr1
 
; see below),
the adaptor of Toll-like receptor sig-
naling MAL (TIRAP), and comple-
ment receptor 1 (CR1, or CD35) (5)
have been implicated in single studies.
An Oxford-Gambia collaboration on
a genome-wide association study has
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Mycobacterial genomics and genetics
 
Genomics has catalyzed Mtb research
and the latest genome sequence, that of
the vaccine strain 
 
Mycobacterium bovis
 
(BCG), reveals that duplication and de-
letion of genes shape genome plasticity
(Stewart Cole, Paris, France). One
gene family of particular interest en-
codes Esx proteins, immunodominant
T cell antigens that are secreted by a
dedicated apparatus (2). Attenuation of
BCG is mainly due to loss of the 
 
esx1
 
locus, which encodes two family mem-
bers, CFP-10 and ESAT-6. Although
their role in pathogenesis is unclear, the
NMR structure of the CFP-10/ESAT-6
complex (Kirsty Lightbody and co-
workers, Leicester, UK) eliminates one
mechanism. Each protein contains two
 
 
 
-helices that interact to form a hetero-
dimeric four-helix bundle (Fig. 1).
Despite reports of association with and
damage to host cell membranes, the
complex presents no hydrophobic
faces, suggesting that these two proteins
alone are unlikely to form a transmem-
brane structure. Secretion of CFP-10
and ESAT-6 requires other genes, not
all of which are closely linked to the
 
esx1
 
 locus in 
 
Mycobacterium marinum
 
(Bryant McLaughlin, San Francisco,
CA) or Mtb (Eric Rubin, Boston,
MA). ESAT-6, CFP-10, and a protein
encoded outside the locus are mutually
dependent for secretion.
Another gene family, occupying
2% of the genome, is required for syn-
thesis of the complex lipids that play
both structural and immunomodu-
latory roles in Mtb. Christophe Guil-
hot (Toulouse, France) delineated the
synthesis pathway of the cell wall–asso-
ciated lipids phthiocerol dimycocerosate
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been launched to enrol up to 2,000 in-
dividuals with TB and 2,000 controls
that will survey 500,000 SNPs in each.
A poster by Mauricio Rojas-López
et al. in Igor Kramnik’s group (Boston,
MA) described a candidate transcrip-
tional regulator, 
 
intracellular pathogen re-
sistance 1
 
 (
 
Ipr1
 
), that is expressed in re-
sistant macrophages after Mtb infection
but is not expressed in susceptible
phagocytes. 
 
Ipr1
 
 appears to foster mac-
rophage apoptosis and confers resis-
tance not only against Mtb but also
against 
 
Listeria monocytogenes
 
 (6).
 
Immune responses
 
Stefan Kaufmann (Berlin, Germany) re-
ported on a mechanism that contributes
to apoptosis in Mtb-infected macro-
phages. Transcriptome analyses of Mtb
from lung specimens obtained from TB
patients revealed marked up-regulation
of the genes 
 
Rv0634
 
 and 
 
Rv2581c
 
,
which both encode putative glyoxylases.
Glyoxylases can detoxify keto-aldehydes
such as methylglyoxal. It was shown that
Mtb-infected cells produce methylgly-
oxal, a tuberculostatic compound that
participates in mycobacteria-induced
host cell apoptosis. Cross priming of T
cells in TB (7) involves apoptosis via a
methylglyoxal-dependent mechanism.
Glyoxylase may thus help defend Mtb
against host-derived methylglyoxal while
also impeding cross-priming.
Hill described phase I clinical trials
of a vaccine consisting of modified
vaccinia virus Ankara encoding an
Mtb mycolyl transferase, antigen 85A
(MVA85A). Profound increases in an-
tigen-specific, IFN-
 
 
 
–producing CD4
T cells were observed in blood from
both MVA85A-vaccinated and BCG-
primed, MVA85A-boosted volunteers
(8). These appear to be the strongest
effector T cell responses yet described
in any human vaccine clinical trial. Pe-
ter Andersen (Copenhagen, Denmark)
described a planned clinical trial using a
fusion protein of Ag85B and ESAT-6
with different adjuvants for intramus-
cular and oral vaccinations. Animal
studies using adenovirus as a carrier for
the fusion protein resulted in strong
CD8 T cell responses and high IFN-
 
 
 
titers. However, these responses were
not paralleled by marked protection
against Mtb replication, although pro-
tein–adjuvant formulations of the same
fusion protein, which induced CD4
IFN-
 
 
 
–secreting T cells, were protec-
tive. Mark Alderson (Corixa) reported
that Corixa has conducted a phase I
trial with a subunit vaccine comprised
of a fusion protein of Rv1196 (a PPE
family protein) and Rv0125 (a putative
serine protease) and an adjuvant. How-
ever, he focused on preclinical studies,
which again demonstrated that IFN-
 
 
 
production generated by CD8 T cells
induced by an adenoviral vector were
not protective. Although protein–adju-
vant vaccines using the GSK Biologi-
cals adjuvants AS02A or AS01B were
protective, neither of these subunit
vaccines afforded better protection in
mice than BCG.
Kaufmann’s group engineered re-
combinant BCG by deleting urease and
introducing the 
 
L. monocytogenes
 
 pore-
forming protein listeriolysin to enhance
presentation of BCG antigens by MHC
class I. The recombinant BCG induced
better protection against Mtb in mice
than native BCG. Although the em-
Figure 1. A ribbon representation of the 
backbone topology of the CFP-10–ESAT-6 
complex. Based on the closest converged structure 
fit to the mean, the model illustrates the two 
helix-turn-helix hairpin structures formed by 
the individual proteins. CFP-10, red; ESAT-6, 
blue. Image provided by Philip Renshaw 
(Leicester, UK).
Figure 2. Schematic description of the underlying mechanism of improved T cell stimulation 
by a novel BCG vaccine. Recombinant BCG deleted in urease and expressing listeriolysin is capable 
of inducing a more profound immune response than wild-type BCG. The likely mechanism involves 
perforation of the phagosomal membrane, which allows leakage into the cytosol of both mycobacterial 
antigens and phagosomal enzymes such as cathepsins. Cathepsins are known to induce apoptosis. 
Thus, the new BCG vaccine strain induces crosspriming leading to a more efficacious immune response. 
Image provided by Stefan Kaufmann (Berlin, Germany) (25).
 
20050842  Page 1694  Tuesday, May 31, 2005  7:49 PM 
JEM VOL. 201, June 6, 2005
 
1695
 
MEETING REVIEW
 
phasis was originally placed on antigen
translocation into the cytosol as a route
to enhanced recognition of infected
host cells by CD8 T cells, this strain has
now been found to induce apoptosis of
infected host cells, leading to cross pre-
sentation (Fig. 2).
Robert North (Saranac Lake, NY)
gave an impressive overview of what
the mouse model has taught us about
host immunity against Mtb that appears
pertinent in humans, including prefer-
ential persistence in the lung, the criti-
cal role of CD4 T cells, the supportive
role of CD8 T cells, the lack of evi-
dence for a role of 
 
 
 
/
 
 
 
 and NKT cells,
and the dependence on tumor necrosis
factor (TNF). Mice have also taught us
the importance of IFN-
 
 
 
 and nitric ox-
ide synthase 2 (NOS2) in protection
against Mtb. However, a nonredundant
role of IFN-
 
 
 
 in defending humans
against Mtb is not as clear as is its non-
redundant role in defense against other
mycobacteria. Although NOS2 is ex-
pressed in human TB (9, 10), there is
no genetic or pharmacological evidence
addressing its contribution to the con-
trol of Mtb infection in humans.
North’s findings in mice (11) high-
light a critical point in vaccine design.
Increasing the number of antigen-spe-
cific memory T cells before challenge
did not afford sterilizing immunity.
Mice were infected with Mtb and then
cured pharmacologically. These mice
responded to a second Mtb infection by
mounting an adaptive, T cell–depen-
dent immune response 5 days earlier
than naive mice. The anamnestic re-
sponse reduced bacterial viability only
10-fold, which was insufficient to pre-
vent lethal pathology. North argued that
the limiting feature of the immune re-
sponse to Mtb may be a defect in mac-
rophage effector function, not an in-
adequate number of antigen-specific T
cells. In this view, vaccination may be
futile if it does no more than induce a
naive host to form Mtb-specific mem-
ory T cells earlier than it would upon
infection. Others were optimistic that
subunit vaccines inducing T helper
1–type CD4 T cell responses will re-
duce death and disease in TB, as they
are doing in mice with other infections.
Although the mechanisms that ac-
count for insufficient T cell–dependent
protection in response to BCG vaccina-
tion and Mtb infection remain unclear,
regulatory T (T reg) cells might be
involved. Willem Hanekom (Cape
Town, South Africa) described the
emergence of T reg cells in children
vaccinated with BCG as newborns. Hill
described induction of the T reg cell
specific transcription factor (FoxP3) in
MVAAg85 vaccinees. A poster from
Simone Joosten et al. from Michel
Klein’s and Tom Ottenhoff’s groups
(Leiden, Netherlands) described activa-
tion of T reg cells after in vitro stimula-
tion with BCG of lymphocytes from
purified protein derivative (PPD)-posi-
tive donors. A poster from Kevin Ur-
dahl et al. in Michael Bevan’s lab (Seat-
tle, WA) reported the emergence of T
reg cells in the lungs of Mtb-infected
mice. Should it turn out that T reg cells
suppress optimal immune responses to
Mtb or BCG, vaccination strategies may
have to include ways to reduce devel-
opment of T reg cells.
Immunodeficiency states are the
major known predisposing factors for
active TB. As reaffirmed by a poster
from Blanca Restrepo et al. (Browns-
ville, TX), diabetes mellitus also consti-
tutes a predisposing factor, but it has never
been clear why. The finding reported in
a poster from Gregory Martens et al. in
Hardy Kornfeld’s lab (Worcester, MA)
that hypercholesterolemia reversibly pre-
disposes mice to severe TB suggests that
dysregulated lipid metabolism, or the
systemic inflammation sometimes associ-
ated therewith, may represent another
category of predisposition that is poten-
tially relevant to the diabetic state (Fig.
3). Given that diabetes and dysregulated
lipid metabolism are reaching epidemic
status, it is important to be alert to a pos-
sible intersection of these disorders with
the TB pandemic.
 
Mycobacterial stress and adaptation
 
Advances in understanding how Mtb
resists and adapts to stresses encoun-
tered during infection are paving the
way toward new interventions. Treha-
lose, the major intracellular sugar of
mycobacteria, protects against cellular
stress, is a component of glycolipids,
and is involved in the transport of my-
colic acids during cell wall biogenesis.
As mammalian cells do not make treha-
lose, its biosynthesis may provide tar-
gets in Mtb, perhaps both in replicat-
ing and nonreplicating organisms. Brian
Robertson (London, UK) reported that,
of the three biosynthetic routes,
only  the OtsAB pathway is essential,
thus prompting the development of a
high-throughput screen for inhibitors
against OtsB2, a trehalose 6-phosphate
phosphatase. However, the late-stage
attenuation of a mutant in an alternate
pathway (
 
treS
 
) implicates the alternate
pathway in persistent infection, either
through synthesis of additional treha-
lose or via its breakdown to glucose
(12). Carl Nathan (New York, NY)
described an approach to TB drug dis-
covery predicated on sensitizing Mtb to
immune attack by reactive nitrogen in-
termediates (RNIs) through targeting
enzymatic components of Mtb’s RNI
defense systems. The approach was il-
lustrated with examples of Mtb en-
zymes involved in macromolecule
repair and degradation—UvrB (13),
mycobacterial proteasomal ATPase
(Mpa) (14) (Fig. 4), and the protea-
somal protease. The attenuation of
 
mpa
 
 and 
 
uvrB
 
 mutants in wild-type
mice, which was partially reversible in
NOS2-deficient mice, supports this ap-
proach. Valerie Mizrahi (Johannesburg,
South Africa) illustrated how Mtb uses
stress to its advantage through the in-
duction of specialized DNA poly-
Figure 3. Hypercholesterolemia predisposes 
to severe TB. ApoE-deficient mice fed on a high 
cholesterol diet develop giant lung inflammatory 
lesions when infected with M. tuberculosis. Image 
provided by Hardy Kornfield (Worcester, MA).
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merases that can generate mutations
following chromosomal DNA dam-
age. The mutagenicity of sub-lethal
doses of fluoroquinolones reported by
Stephen Gillespie (London, UK) is
likely mediated by the error-prone
DnaE2 polymerase (15) following
drug-induced DNA damage (16) and
can promote resistance to other antibi-
otics, such as rifampin. This has impor-
tant implications for the evolution of
drug resistance in Mtb in light of the
increased use of fluoroquinolones in
TB therapy. William Bishai (Baltimore,
MD) reported that the “immunopa-
thology” (
 
imp
 
) phenotype displayed in
mice by an Mtb mutant in the alternate
sigma factor, SigC (17), switches to a
 
giv
 
 (growth in vivo; attenuated) pheno-
type when assessed in guinea pigs. This
underscores that the phenotype of a
mutant depends on the conditions to
which the organism must adapt, and
that we have little understanding of
how conditions in one animal model
relate to those in another.
 
Animal models
 
There is a consensus that mice, guinea
pigs, rabbits, and cynomologus ma-
caques infected with Mtb model
overlapping features of human TB. A
controversial variant of this view is that
the larger the animal, the better it
models human disease. According to
the latter view, two of the shortcom-
ings of mice as a model are that all mice
eventually succumb to Mtb infection,
as opposed to 5–10% of immunocom-
petent humans; and that mice fail to
develop necrotic lesions, the precursors
of the cavities characteristic of ad-
vanced TB in humans. However,
North pointed out that mice deficient
in IFN-
 
 
 
, NOS2, or TNF 
 
do
 
 develop
necrotic lesions. To this list can be
added mice lacking 
 
Ipr1
 
 (6) and those
of the I/St strain (18). That some in-
bred strains of mice respond to Mtb
with necrotic lung lesions but most do
not, could be considered to mimic the
distribution of responses to Mtb in in-
fected, outbred humans. That is, the
small minority of HIV-negative people
who respond to Mtb infection by de-
veloping symptomatic, necrotizing TB
lesions may have immunologic features
similar to mice whose genetics predis-
pose to a necrotic response.
Mtb deficient in the transcription
factor 
 
whiB
 
 described in a poster by John
Trombley et al. in Adrie Steyn’s lab (Bir-
mingham, AL) and the 
 
sigC-
 
deficient
Mtb studied by Bishai displayed strik-
ingly different phenotypes in mice and
guinea pigs. Thus, it is possible that the
animal species that best models human
TB may vary not just with the aspect of
TB being considered but also with the
genetic makeup of the infecting strain.
JoAnne Flynn (Pittsburgh, PA) re-
ported that macaques infected with
Mtb by the pulmonary route sorted
spontaneously into latently infected
(60%) and clinically diseased (40%)
subsets, enabling many imortant analy-
ses. However, the high proportion of
animals that develop active disease and
the lack of a demonstrable delayed type
hypersensitivity response to PPD in the
macaque represent distinct differences
from the human situation.
Lalita Ramakrishnan (Seattle, WA)
showed that zebrafish develop caseating
granulomas upon infection with 
 
M.
marinum
 
 (19). Thus, necrotic responses
to mycobacteria are not confined to
large hosts.
Clifton Barry (Rockville, MD) sug-
gested that in macaques tuberculous le-
sions are hypoxic, with such profound
impact on Mtb’s metabolism that the
study of host species with predomi-
nantly nonhypoxic lesions can be fun-
damentally misleading. David Sherman
(Seattle, WA) reported that Mtb defi-
cient in DosR, a master regulator of hy-
poxic responses, had no phenotype in
mice. Stefan Ehlers (Borstel, Germany)
speculated that this might reflect lack of
severe hypoxia in tuberculous lesions in
mice. However, it is not yet clear
whether animal models differ amongst
themselves with regard to the extent of
oxygenation in tuberculous lesions as
much as the diverse lesional microenvi-
ronments may differ in a given host.
Nathan noted that the prevalence of ni-
trotyrosine within human tuberculous
lesions (9, 10) and the reported 
 
K
 
m
 
 of
NOS2 for O
 
2
 
 (reported values range
from 6–135 
 
 
 
M) (20) suggest that hu-
man TB lesions support functionally
relevant O
 
2
 
-dependent biochemistry.
At the same time, hypoxia may mark-
edly limit the rate of NO generation,
contributing to escape of Mtb from im-
mune control. It remains an important
challenge to quantify O
 
2
 
 and NO con-
centrations in the microenvironments
of tuberculous lesions in humans and
experimental animals.
 
New technologies and research resources
 
Target validation by conditional gene
silencing has been hampered by limited
knowledge of tightly regulated pro-
moters for use in mycobacteria (21).
An important step has been taken to
address this need through the develop-
ment of a range of tetracycline-regu-
lated gene expression systems by Sabine
Ehrt and Dirk Schnappinger (New
York, NY), Robertson, Tanya Parish
(London, UK), and Bishai and their
colleagues (22–24). The successful ap-
plication of these systems to condi-
tional gene silencing in vitro, coupled
with the accessibility of intracellular
bacteria to the tetracycline inducer,
suggests that the elusive goal of being
able to silence Mtb genes at specific
stages of infection may be attainable.
Finally, a major contributor to the
growing sense of Mtb as a model or-
ganism was the emergence of special
Figure 4. Electron microscope images of the hexameric mycobacterial proteasome ATPase (Mpa). 
Compilation by Z. Chen and H. Li; images rotated about their axis (1–5) to display the arbitrarily 
designated “top” (T) and “bottom” (B) of the complex. Reproduced from reference 13 by permission.
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resources for the Mtb research commu-
nity. Table S1 offers a compendium of
resources, including some announced
at the meeting, and is available online
at http://www.jem.org/cgi/content/
full/jem.20050842/DC1.
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